MHRA has issued a patient safety alert for glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are in short supply until at least mid-2024.

The alert strongly discourage the off-label use of these agents for the management of obesity. It states that existing stock must be conserved for use in patients with diabetes. These shortages have serious clinical implications in the management of patients with type 2 diabetes.